In individuals who are deficient in CYP2D6, coadministration of modafinil with substrates of CYP2D6 which have ancillary routes of elimination through CYP2C19 (eg, tricyclic antidepressants and selective serotonin reuptake inhibitors) may perhaps lead to elevated circulating amounts of these drugs and have to have dose adjustment (Robertson et al 2